Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEDAR |
Company Contact | |
Address: | 2820 Granville St VANCOUVER BC V6C 1S4 |
Tel: | N/A |
Website: | www.aequuspharma.ca |
IR: | See website |
Key People | ||
Douglas Glen Janzen Chairman of the Board, President, Chief Executive Officer | Ann Fehr Chief Financial Officer | Anne Michelle Stevens Vice President - Corporate Development, Executive Director, Secretary |
Business Overview |
Aequus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products. The Company operates through the segment of sales and marketing of pharmaceutical drugs developed by the Company or by its collaborative partners. Its products include tacrolimus immediate releaser, which is an immunosuppressive therapy used for the treatment and prevention of acute rejection following organ transplantation; Vistitan, which is a ophthalmology product; Topiramate extended-release (XR), which is a once-daily topiramate product designed for patient compliance, and Oxcarbazepine XR, which is a once-daily oxcarbazepine product. Its development-stage pipeline includes various products in neurology and psychiatry. Its lead development-stage product candidate is AQS-1301. In addition, the Company is developing a pipeline of other central nervous system product candidates. It has over two preclinical-stage programs and a clinical-stage program in development. |
Financial Overview |
For the nine months ended 30 September 2019, Aequus Pharmaceuticals Inc revenues decreased 6% to C$1.1M. Net loss decreased 3% to C$2.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research and Development Expense - Balan decrease of 78% to C$67K (expense), General administration - Balancing value decrease of 15% to C$1.1M (expense). |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $11.70M as of Sep 30, 2019 |
Annual revenue (TTM): | $1.33M as of Sep 30, 2019 |
EBITDA (TTM): | -$2.47M as of Sep 30, 2019 |
Net annual income (TTM): | -$2.74M as of Sep 30, 2019 |
Free cash flow (TTM): | -$1.92M as of Sep 30, 2019 |
Net Debt Last Fiscal Year: | $0.99M as of Sep 30, 2019 |
Shares outstanding: | 80,437,970 as of Sep 30, 2019 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |